Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis
Author:
Publisher
Wiley
Subject
Pharmacology
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1476-5381.2010.01183.x/fullpdf
Reference128 articles.
1. Inhibition of Toll-like receptor 4 breaks the inflammatory loop in autoimmune destructive arthritis;Abdollahi-Roodsaz;Arthritis Rheum,2007
2. Shift from toll-like receptor 2 (TLR-2) toward TLR-4 dependency in the erosive stage of chronic streptococcal cell wall arthritis coincident with TLR-4-mediated interleukin-17 production;Abdollahi-Roodsaz;Arthritis Rheum,2008a
3. Stimulation of TLR2 and TLR4 differentially skews the balance of T cells in a mouse model of arthritis;Abdollahi-Roodsaz;J Clin Invest,2008b
4. Local interleukin-1-driven joint pathology is dependent on toll-like receptor 4 activation;Abdollahi-Roodsaz;Am J Pathol,2009
5. Use of pharmacodynamic/pharmacokinetic modelling for starting dose selection in first-in-human trials of high-risk biologics;Agoram;Br J Clin Pharmacol,2009
Cited by 25 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Toward Overcoming Treatment Failure in Rheumatoid Arthritis;Frontiers in Immunology;2021-12-23
2. Characterization of concurrent target suppression by JNJ-61178104, a bispecific antibody against human tumor necrosis factor and interleukin-17A;mAbs;2020-01-01
3. Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan;Journal of Medical Economics;2019-05-15
4. Era of biosimilars in rheumatology: reshaping the healthcare environment;RMD Open;2019-05
5. Pharmacokinetics, Pharmacodynamics, Immunogenicity, Safety, and Tolerability of JNJ-61178104, a Novel Tumor Necrosis Factor-Alpha and Interleukin-17A Bispecific Antibody, in Healthy Subjects;The Journal of Clinical Pharmacology;2019-02-18
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3